Crexavibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb – Research Grade

Introduction

Crexavibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb – Research Grade is a novel monoclonal antibody (mAb) that has been developed as a potential therapeutic for the treatment of COVID-19. This biosimilar is designed to target the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, which is responsible for viral entry into host cells. In this article, we will provide a scientific description of Crexavibart Biosimilar, including its structure, activity, and potential applications.

Structure of Crexavibart Biosimilar

Crexavibart Biosimilar is a recombinant mAb that is produced in mammalian cells using advanced biotechnology techniques. It is a fully humanized antibody, meaning that it is derived from human genetic material and is less likely to cause an immune response in patients. The antibody has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains, connected by disulfide bonds. The variable regions of the antibody, which are responsible for binding to the target antigen, are located at the tips of the heavy and light chains.

Activity of Crexavibart Biosimilar

Crexavibart Biosimilar is specifically designed to target the RBD of the SARS-CoV-2 spike protein. This region is critical for viral entry into host cells, as it binds to the angiotensin-converting enzyme 2 (ACE2) receptor on the surface of human cells. By binding to the RBD, Crexavibart Biosimilar prevents the virus from attaching to and entering host cells, thereby inhibiting viral replication and spread.

In addition to its ability to block viral entry, Crexavibart Biosimilar also has potent neutralizing activity against SARS-CoV-2. This means that it can bind to and inactivate the virus, preventing it from infecting other cells. This neutralizing activity is crucial for the effectiveness of any potential COVID-19 treatment, as it can limit the severity and duration of the infection.

Applications of Crexavibart Biosimilar

Crexavibart Biosimilar has potential applications in the treatment of COVID-19. As a biosimilar, it is intended to be highly similar to an already approved mAb therapy for COVID-19, making it a promising candidate for clinical trials and potential regulatory approval. This antibody has the potential to be used as a standalone therapy or in combination with other treatments for COVID-19, such as antiviral drugs.

In addition to its potential therapeutic applications, Crexavibart Biosimilar also has potential diagnostic and research uses. The antibody can be used in diagnostic tests to detect the presence of SARS-CoV-2 in patient samples. It can also be used in research studies to better understand the structure and function of the virus, as well as to develop new treatments and vaccines.

Conclusion

Crexavibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb – Research Grade is a promising new monoclonal antibody therapy for COVID-19. Its structure, activity, and potential applications make it a valuable addition to the growing arsenal of treatments for this global pandemic. Further research and clinical trials will be needed to fully evaluate the effectiveness and safety of this biosimilar, but it holds great promise for the future of COVID-19 treatment.

ProteoGenix catalogue number PX-TA1829. For research use only.

Target: Crexavibart Biosimilar – Anti-SARS-CoV-2 Spike RBD mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet